GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Cash Flow from Financing

Sanofi (Sanofi) Cash Flow from Financing

: $-229 Mil (TTM As of Jun. 2023)
View and export this data going back to 2002. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2023, Sanofi paid $0 Mil more to buy back shares than it received from issuing new shares. It received $0 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0 Mil from paying cash dividends to shareholders. It received $0 Mil on other financial activities. In all, Sanofi spent $0 Mil on financial activities for the six months ended in Jun. 2023.


Sanofi Cash Flow from Financing Historical Data

The historical data trend for Sanofi's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,658.89 -7,889.29 -7,972.88 -6,166.31 -8,780.81

Sanofi Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -5,924.95 -228.81 - -

Sanofi Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Sanofi's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Flow from Financing(A: Dec. 2023 )
=Issuance of Stock+Repurchase of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=212.65+-646.674+-3419.847+0+-4857.143+-69.793
=-8,781

Sanofi's Cash from Financing for the quarter that ended in Jun. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-229 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi  (NAS:SNY) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Sanofi's issuance of stock for the six months ended in Jun. 2023 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Sanofi's repurchase of stock for the six months ended in Jun. 2023 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Sanofi's net issuance of debt for the six months ended in Jun. 2023 was $0 Mil. Sanofi received $0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Sanofi's net issuance of preferred for the six months ended in Jun. 2023 was $0 Mil. Sanofi paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Sanofi's cash flow for dividends for the six months ended in Jun. 2023 was $0 Mil. Sanofi received $0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Sanofi's other financing for the six months ended in Jun. 2023 was $0 Mil. Sanofi received $0 Mil on other financial activities.


Sanofi Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Sanofi's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi (Sanofi) Business Description

Address
46, avenue de la Grande Armée, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.